Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

MRK

Merck & Co Inc

149.70

Aug 19 • 11:05 AM ET +14.53 (10.75%)

Healthcare Drug Manufacturers - General USA Mega NYSE

Today, 6:55 AMMerck and Moderna Phase 3 INTerpath-001 topline data show V940 plus Keytruda met primary and key secondary endpoints in melanoma

Peers: LLY JNJ ABBV AZN PFE BMY NVS AMGN GSK SNY

| Held by: VTI VOO SCHD IVV SPY VTV XLV VIG VYM VHT

Scroll to Statements

Index	DJIA, S&P 500
Market Cap	369.34B
Enterprise Value	416.11B
Income	3.17B
Sales	66.29B
Book/sh	16.99
Cash/sh	2.91
Dividend Est.	3.41 (2.28%)
Dividend TTM	3.36 (2.24%)
Dividend Ex-Date	Sep 15, 2026
Dividend Gr. 3/5Y	5.42% 5.75%
Payout	45.05%
Employees	75000
IPO	Jun 15, 1946

P/E	119.65
Forward P/E	15.66
PEG	2.80
P/S	5.57
P/B	8.81
P/C	51.43
P/FCF	22.99
EV/EBITDA	21.89
EV/Sales	6.28
Quick Ratio	1.10
Current Ratio	1.32
Debt/Eq	1.29
LT Debt/Eq	1.22
Option/Short	Yes / Yes

EPS (ttm)	1.25
EPS next Y	9.56
EPS next Q	2.22
EPS this Y	-69.38%
EPS next Y	247.68%
EPS next 5Y	5.59%
EPS past 3/5Y	8.43% 21.23%
Sales past 3/5Y	3.55% 9.34%
EPS Y/Y TTM	-80.62%
Sales Y/Y TTM	4.51%
EPS Q/Q	-130.68%
Sales Q/Q	4.94%
Earnings	Aug 04 BMO
EPS/Sales Surpr.	51.94% 1.45%

Insider Own	0.11%
Insider Trans	-7.76%
Inst Own	81.94%
Inst Trans	-0.75%
ROA	2.57%
ROE	6.98%
ROIC	3.41%
Gross Margin	72.43%
Oper. Margin	18.81%
Profit Margin	4.79%
SMA20	13.32%
SMA50	18.16%
SMA200	30.61%
Trades

Shs Outstand	2.47B
Shs Float	2.46B
Short Float	1.15%
Short Ratio	2.77
Short Interest	28.28M
52W High	137.98 8.49%
52W Low	77.58 92.96%
Volatility	2.43% 2.36%
ATR (14)	4.20
RSI (14)	81.77
Beta	0.21
Rel Volume	5.51
Avg Volume	10.21M
Volume	15,840,049

Perf Week	12.62%
Perf Month	18.56%
Perf Quarter	31.04%
Perf Half Y	23.05%
Perf YTD	42.22%
Perf Year	76.26%
Perf 3Y	37.09%
Perf 5Y	90.80%
Perf 10Y	147.78%
Recom	1.84
Target Price	138.48
Prev Close	135.17
Price	149.70
Change %	10.75%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-26	Upgrade	Daiwa Securities	Neutral → Outperform	$143
May-06-26	Resumed	Citigroup	Neutral	$125
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$142
Feb-20-26	Initiated	Barclays	Overweight	$140
Feb-13-26	Upgrade	Deutsche Bank	Hold → Buy	$150
Jan-08-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$135
Dec-18-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$130
Nov-24-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$125
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$105
Oct-13-25	Resumed	Citigroup	Neutral	$95
Sep-17-25	Downgrade	Berenberg	Buy → Hold	$90
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform

Show Previous Ratings

Today 10:46AM	Moderna Stock Jumps 86% on First mRNA Cancer Trial Win (GuruFocus.com) +10.75%
10:43AM	Moderna & Merck stocks skyrocket on their cancer vaccine trial's success. Here's what to know. (Yahoo Finance Video)
10:16AM	Moderna Stock Eyes Best Day Ever After Cancer Vaccine Breakthrough (Schaeffer's Research)
10:14AM	Tech sell-off resumes, counterbalancing bond yield relief: AlphaCheck (Yahoo Finance)
10:09AM	Moderna Stock Explodes Over 100% After Cancer Vaccine Breakthrough (BeInCrypto)
09:38AM	Loading…
09:38AM	Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls (The Fly)
09:29AM	Moderna Shares Surge More Than 90% After Phase 3 Melanoma Trial Success (InvestorsHub)
09:06AM	Wall St set for higher open after retail earnings; Moderna soars (Reuters)
08:28AM	Moderna stock is soaring in premarket after encouraging trial of cancer vaccine (MarketWatch)
08:15AM	Moderna's stock doubles on promising cancer-vaccine results (MarketWatch)
08:11AM	MRNA Stock Heads For Its Best Ever Day After Melanoma Therapy Meets Primary Goal (Stocktwits)
07:59AM	Premarket movers: Moderna jumps after Phase 3 trial; Target slides (Investing.com)
07:38AM	Moderna's Cancer Breakthrough Just Sent the Stock Soaring (Barrons.com)
07:37AM	Moderna shares soar 60% on melanoma vaccine trial success (Financial Times)
07:35AM	Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market (Barrons.com)
07:17AM	Loading…
07:17AM	Moderna, Merck Stock Jumps on Melanoma Vaccine News (The Wall Street Journal)
06:45AM	Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma (Business Wire)
06:45AM	At Last, a Successful Cancer Vaccine from Merck and Moderna (Barrons.com)
06:30AM	HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation (TMX Newsfile)
05:30AM	The Key to Pharma M&A: Never Shopping Hungry (The Wall Street Journal)
Aug-18-26 02:35PM	The 5 Safest Vanguard Funds to Own in a Volatile Market (Kiplinger)
12:48AM	Why Did ROKU, MRK, SCHW Stocks Jump To 52-Week Highs? (Stocktwits)
Aug-17-26 05:29PM	Why Isn't Eli Lilly Stock Trading At The Top Of Its Peer Group? (Trefis)
11:28AM	What The Headline Growth Rate Hides About JNJ Stock (Trefis)
Aug-14-26 05:22PM	AbbVie Defends Its Turf, But Leaves One Big Question Open (Trefis)
Aug-13-26 12:10PM	The Sharpest Exchanges From ABBV's Earnings Call (Trefis)
Aug-12-26 04:49PM	How ABBV Stock Moved Away From Its Peer Group (Trefis)
03:17PM	Amgen Stock And The Price Of A Promise (Trefis)
07:16AM	Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs (Pharmaceutical Technology)
Aug-11-26 07:09PM	JNJ Keeps Climbing. Should You Climb On? (Trefis)
05:38PM	Loading…
05:38PM	$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off (Trefis)
Aug-10-26 07:01PM	What Analysts Really Pressed LLY On This Quarter (Trefis)
03:21PM	Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) (FinanceWire)
12:01PM	Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection (Trefis)
Aug-07-26 02:38PM	The Two Divergent Paths Priced Into Eli Lilly Stock (Trefis)
11:30AM	These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks (Barrons.com)
06:43AM	Morning Bid: Dealjà vu (Reuters)
12:01AM	For Modernas Greenlit mRNA Flu Vaccine, Payoff Is a Ways Off (The Daily Upside)
Aug-06-26 07:04AM	MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data (Clinical Trials Arena)
06:45AM	U.S. FDA Accepts sBLA for ENFLONSIA (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season (Business Wire)
02:01AM	Merck KGaA Q2 adjusted profit rises 9%, hikes FY outlook (Investing.com)
Aug-05-26 05:23PM	Why PFE Stock Hands You So Much Cash Right Now (Trefis)
07:02AM	MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease (Clinical Trials Arena)
07:00AM	Earnings roundup: Gileads uncertain future, Pfizers crossroads and Mercks PCSK9 launch (BioPharma Dive)
05:08AM	Merck is pharmas most patent-exposed company. Now its reinventing itself. (Pharma Voice)
01:17AM	Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive (Stocktwits)
Aug-04-26 06:41PM	Merck & Co., Inc. Q2 2026 Earnings Call Summary (Moby)
05:02PM	Merck & Co Inc (MRK) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
04:12PM	Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story (Barrons.com)
03:23PM	The $85 Billion Consolation Prize For JNJ Shareholders (Trefis)
12:35PM	Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine (Barrons.com)
08:19AM	Merck Shares Advance After Strong Second-Quarter Earnings and Higher Revenue Outlook (InvestorsHub)
08:07AM	Merck cuts 2026 profit forecast on Terns acquisition charges (Quartz)
07:12AM	Merck shares rise on big Q2 earnings beat, adjusted FY outlook (Investing.com)
06:37AM	Merck: Q2 Earnings Snapshot (Associated Press)
06:30AM	Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street? (Barrons.com)
06:30AM	Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline (Business Wire)
Aug-03-26 07:14PM	$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off (Trefis)
05:05PM	AbbVie's Growth Now Leans On A Single Molecule (Trefis)
Jul-31-26 10:26AM	The Signs Before Eli Lilly Stock Surged Were All On The Record (Trefis)
10:07AM	LLY Stock: Collect 12% Now, In Exchange For Capping Upside At 15% (Trefis)
01:00AM	Here Comes the Next Wave of GLP-1s. They'll Treat a Lot More Than Obesity. (Barrons.com)
Jul-29-26 03:27PM	The Week Ahead: Jobs Data, Top 10 Earnings Reports to Watch (Schaeffer's Research)
02:11PM	The Real Price of AbbVie Stock Is Cheaper Than You Think (Trefis)
11:04AM	Merck Announces Fourth-Quarter 2026 Dividend (Business Wire)
Jul-28-26 04:52PM	What Johnson & Johnson Stock Told You Before It Surged (Trefis)
04:41PM	Does Eli Lilly Stock Actually Diversify Your Portfolio? (Trefis)
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com)
03:54PM	The Engine Behind ABBV Stock Has Real Parts (Trefis)
02:33PM	Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips (Trefis)
02:50AM	Johnson & Johnson Now Leads Its Pitch With An Oncology Bet (Trefis)
Jul-25-26 10:30AM	Johnson & Johnson Is Becoming A Narrower Company Than You Bought (Trefis)
Jul-23-26 01:31PM	Best Monthly Dividend ETFs for Consistent Income (Kiplinger)
Jul-22-26 09:17AM	LLY Has Momentum. The Question Is The Price (Trefis)
01:30AM	Trade Options When Others Are Fearful (Barrons.com)
Jul-21-26 04:04PM	Eli Lilly Stock And The Price Of Confidence (Trefis)
02:31PM	AbbVie Stock Zigs When The Market Zags (Trefis)
10:00AM	Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure (Business Wire)
Jul-20-26 02:55PM	Reading Between The Lines Of JNJ Stock's Latest Call (Trefis)
01:45PM	Eli Lilly Stock And The Price Of Confidence (Trefis)
08:17AM	Merck's Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. (Barrons.com)
02:00AM	What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment. (Barrons.com)
Jul-17-26 05:51PM	The Real Question Buried Inside Merck Stock's Premium Price (Trefis)
08:40AM	New Cholesterol Pill, Earnings Growth Boost Merck Shares (FX Empire)
06:31AM	MSD wins FDA approval for cholesterol pill to help plug Keytruda void (Pharmaceutical Technology)
05:21AM	GSK shelves cough drug acquired in $2B deal (BioPharma Dive)
Jul-16-26 07:27PM	Why Is PSNL Stock Up 5% After-Hours? (Stocktwits)
04:45PM	FDA approves first-of-its-kind cholesterol pill Lipfendra: What it will cost (Yahoo Personal Finance)
04:10PM	Nasdaq Sinks as Chip Stocks Drop Again: Stock Market Today (Kiplinger)
09:19AM	What Could Push LLY Stock Higher From Here? (Trefis)
09:19AM	The Real Engine Behind Johnson & Johnson Stock's Next Climb (Trefis)
08:44AM	Why Is The Market Punishing JNJ Stock? (Trefis)
08:17AM	Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill (Barrons.com)
06:45AM	Merck's LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia (Business Wire)
06:45AM	Merck Gets Approval for Powerful Cholesterol-Cutting Pill (Barrons.com)
05:22AM	Merck wins first approval of a PCSK9 cholesterol pill (BioPharma Dive)
Jul-15-26 07:41AM	Merck ADC, in China study, shows potential to replace chemo in lung cancer (BioPharma Dive)
07:00AM	Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026 (Business Wire)
06:45AM	KEYTRUDA (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy (Business Wire)
Jul-14-26 01:54PM	What Lilly's Peer-Beating Numbers Cost You (Trefis)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

ChairmanMr. Robert M. Davis J.D.

Executive VP & CFOMs. Caroline A. Litchfield

Executive VP & General CounselMs. Jennifer L. Zachary J.D.

Ph.D.Dr. Dean Y. Li M.D.

Senior VP of FinanceMr. Dalton E. Smart III

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guindo Chirfi	EVP, Access, Policy & Comms	Aug 13 '26	Sale	135.00	10,000	1,350,000	36,613	Aug 13 05:02 PM
CHIRFI GUINDO	Officer	Aug 13 '26	Proposed Sale	135.00	10,000	1,350,000		Aug 13 04:15 PM
Zachary Jennifer	EVP, General Counsel	Aug 12 '26	Option Exercise	109.78	54,927	6,029,637	125,824	Aug 13 04:11 PM
Zachary Jennifer	EVP, General Counsel	Aug 12 '26	Sale	133.46	80,315	10,718,495	45,509	Aug 13 04:11 PM
RICHARD ROBERT DELUCA JR	Officer	Aug 12 '26	Proposed Sale	131.63	11,699	1,539,992		Aug 12 04:23 PM
JENNIFER L ZACHARY	Officer	Aug 12 '26	Proposed Sale	133.46	80,315	10,718,495		Aug 12 04:19 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 10 '26	Sale	130.43	20,784	2,710,951	134,703	Aug 12 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 11 '26	Sale	131.76	12,837	1,691,426	121,866	Aug 12 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 12 '26	Sale	131.63	11,699	1,539,992	110,167	Aug 12 04:10 PM
RICHARD ROBERT DELUCA JR	Officer	Aug 11 '26	Proposed Sale	131.76	12,837	1,691,426		Aug 11 04:14 PM
RICHARD ROBERT DELUCA JR	Officer	Aug 10 '26	Proposed Sale	130.43	20,784	2,710,951		Aug 10 04:43 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Aug 06 '26	Sale	130.38	6,050	788,773	155,487	Aug 10 04:28 PM
Maraldo David R.	EVP & Pres. MMD	Aug 05 '26	Option Exercise	82.25	18,706	1,538,495	27,921	Aug 07 04:21 PM
Maraldo David R.	EVP & Pres. MMD	Aug 05 '26	Sale	128.72	18,706	2,407,797	18,212	Aug 07 04:21 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Aug 05 '26	Option Exercise	74.49	52,847	3,936,377	66,421	Aug 07 04:19 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Aug 05 '26	Sale	128.77	52,847	6,805,145	31,716	Aug 07 04:19 PM
Guindo Chirfi	EVP, Access, Policy & Comms	Aug 06 '26	Sale	131.00	15,000	1,965,000	46,613	Aug 07 04:17 PM
CHIRFI GUINDO	Officer	Aug 06 '26	Proposed Sale	131.00	15,000	1,965,000		Aug 06 04:47 PM
RICHARD ROBERT DELUCA JR	Officer	Aug 06 '26	Proposed Sale	130.38	6,050	788,773		Aug 06 04:45 PM
DAVID M WILLIAMS	Officer	Aug 05 '26	Proposed Sale	128.77	52,847	6,805,145		Aug 05 04:27 PM
DAVID MARALDO	Officer	Aug 05 '26	Proposed Sale	128.72	18,706	2,407,797		Aug 05 04:26 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '26	Option Exercise	112.16	383	42,957	9,520	May 05 01:51 PM
Maraldo David R.	EVP & Pres. MMD	May 02 '26	Option Exercise	112.16	552	61,912	18,371	May 05 01:47 PM
Guindo Chirfi	EVP, Access, Policy & Comms	Apr 29 '26	Option Exercise	110.03	1,967	216,429	62,582	May 01 06:54 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 29 '26	Option Exercise	110.03	2,597	285,748	16,477	May 01 06:32 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 29 '26	Option Exercise	110.03	2,518	277,056	162,778	May 01 06:20 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Apr 29 '26	Option Exercise	110.03	1,377	151,511	32,395	May 01 05:56 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 29 '26	Option Exercise	110.03	944	103,868	9,156	May 01 05:55 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '26	Option Exercise	110.95	464	51,481	9,296	May 01 05:55 PM
Li Dean Y	Executive VP & President, MRL	Apr 29 '26	Option Exercise	110.03	4,722	519,562	96,757	May 01 05:45 PM
Zachary Jennifer	EVP, General Counsel	Apr 29 '26	Option Exercise	110.03	2,951	324,699	72,351	May 01 05:43 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '26	Option Exercise	110.95	11,350	1,259,282	18,917	May 01 05:42 PM
Larson Betty D	EVP, Chief HR Officer	Apr 29 '26	Option Exercise	110.03	2,085	229,413	8,282	May 01 05:42 PM
Litchfield Caroline	EVP & CFO	Apr 29 '26	Option Exercise	110.03	3,935	432,968	94,239	May 01 05:39 PM
Davis Robert M	Chairman, CEO & President	Apr 29 '26	Option Exercise	110.03	13,300	1,463,399	456,902	May 01 05:38 PM
Oosthuizen Johannes Jacobus	EVP, Oncology & Int?l	Apr 29 '26	Option Exercise	110.03	1,377	151,511	22,574	May 01 05:34 PM
Guindo Chirfi	Chief Marketing Officer	Feb 12 '26	Sale	121.46	10,000	1,214,562	60,615	Feb 12 04:02 PM
DEAN LI	Officer	Feb 10 '26	Proposed Sale	117.52	10,235	1,202,844		Feb 10 04:38 PM
Li Dean Y	Executive VP & President, MRL	Feb 10 '26	Sale	117.52	10,235	1,202,844	92,035	Feb 10 04:04 PM
JENNIFER ZACHARY	Officer	Feb 09 '26	Proposed Sale	119.15	121,573	14,485,690		Feb 09 04:57 PM
CHIRFI GUINDO	Officer	Feb 09 '26	Proposed Sale	118.41	20,000	2,368,202		Feb 09 04:55 PM
Guindo Chirfi	Chief Marketing Officer	Feb 09 '26	Sale	118.41	10,000	1,184,101	70,615	Feb 09 04:04 PM
Zachary Jennifer	EVP, General Counsel	Feb 09 '26	Option Exercise	119.15	121,573	14,485,690	125,708	Feb 09 04:01 PM
Zachary Jennifer	EVP, General Counsel	Feb 09 '26	Sale	119.15	121,573	14,485,690	68,916	Feb 09 04:01 PM
RICHARD ROBERT DELUCA JR.	Officer	Feb 06 '26	Proposed Sale	120.92	37,685	4,557,025		Feb 06 04:35 PM
DAVID WILLIAMS	Officer	Feb 06 '26	Proposed Sale	121.91	5,000	609,525		Feb 06 04:33 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 06 '26	Option Exercise	77.62	5,000	388,100	35,838	Feb 06 04:20 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 06 '26	Sale	121.91	5,000	609,525	30,838	Feb 06 04:20 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 06 '26	Proposed Sale	121.87	15,000	1,827,992		Feb 06 04:19 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Feb 04 '26	Option Exercise	62.07	4,000	248,280	14,605	Feb 06 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Feb 04 '26	Sale	119.67	6,400	765,920	8,205	Feb 06 04:18 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 06 '26	Sale	121.87	15,000	1,827,992	21,197	Feb 06 04:15 PM
Litchfield Caroline	EVP & CFO	Feb 04 '26	Option Exercise	53.06	41,997	2,228,361	132,189	Feb 06 04:13 PM
Litchfield Caroline	EVP & CFO	Feb 04 '26	Sale	119.61	41,997	5,023,312	90,192	Feb 06 04:13 PM
Li Dean Y	Executive VP & President, MRL	Feb 04 '26	Option Exercise	56.04	15,087	845,475	117,357	Feb 06 04:12 PM
Li Dean Y	Executive VP & President, MRL	Feb 04 '26	Sale	118.77	15,087	1,791,824	102,270	Feb 06 04:12 PM
Guindo Chirfi	Chief Marketing Officer	Feb 05 '26	Sale	121.88	20,000	2,437,676	80,615	Feb 06 04:10 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Feb 06 '26	Sale	120.92	37,685	4,557,025	160,174	Feb 06 04:08 PM
Davis Robert M	Chairman, CEO & President	Feb 04 '26	Sale	118.04	47,434	5,599,327	443,602	Feb 06 04:05 PM
CHIRFI GUINDO	Officer	Feb 05 '26	Proposed Sale	121.88	20,000	2,437,676		Feb 05 04:25 PM
DALTON SMART	Officer	Feb 04 '26	Proposed Sale	119.67	6,400	765,920		Feb 04 04:38 PM
ROBERT M. DAVIS	Officer	Feb 04 '26	Proposed Sale	118.02	47,434	5,598,137		Feb 04 04:29 PM
DEAN LI	Officer	Feb 04 '26	Proposed Sale	118.77	15,087	1,791,824		Feb 04 04:27 PM
CAROLINE A LITCHFIELD	Officer	Feb 04 '26	Proposed Sale	119.61	41,997	5,023,312		Feb 04 04:26 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Nov 10 '25	Sale	87.00	7,085	616,395	0	Nov 12 04:01 PM
CRISTAL DOWNING	Officer	Nov 10 '25	Proposed Sale	87.00	7,085	616,395		Nov 10 04:07 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Nov 03 '25	Sale	83.59	8,614	720,040	24,578	Nov 04 04:02 PM
DAVID WILLIAMS	Officer	Nov 03 '25	Proposed Sale	83.59	8,614	720,040		Nov 03 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your Finviz experience